JOIN US FOR A LIVE MEETING PRESENTATION

TREMFYA® in Focus:

Multispecialty Insights From a Rheumatologist, Dermatologist, and Gastroenterologist

Tremfya® (guselkumab)

DATE

Friday, March 14, 2025

7:00 PM - 8:00 PM Eastern

LOCATION

Live Product Theater at the NCRA Meeting Conference

Nanasteak
345 Blackwell Street, Durham, NC 27701

AGENDA TOPICS

Understanding the relationship between PsO, PsA, and UC

Choosing TREMFYA® for adult patients with moderate to severe plaque PsO or active PsA, or moderately to severely active UC

Exploring TREMFYA® clinical data in moderate to severe plaque PsO, active PsA and moderately to severely active UC

How to help your patients start and stay on TREMFYA® with support from TREMFYA withMe

PsA=psoriatic arthritis; PsO=psoriasis; UC=ulcerative colitis.

PRESENTED BY

Sergio Schwartzman, MD
Rheumatologist
Schwartzman Rheumatology
New York, NY

Diana Whitehead, MD
Gastroenterologist
Woodholme Gastroenterology Associates
Baltimore, MD

This program is developed and offered by Johnson & Johnson. This is not an official program of the American College of Rheumatology. Speakers are being compensated by Johnson & Johnson for participation in this program.

Register at

MyDomeProgramRegistration.com

Enter Meeting Code: 2025-00156

Please note that your e-mail will be required for registration. The information you provide will only be used to facilitate your attendance at this program. If you have questions about this program, please contact your Johnson & Johnson, representative. SPONSORED BY JOHNSON & JOHNSON. Speakers are being compensated for participation in this program.

INDICATIONS

TREMFYA® (guselkumab) is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

TREMFYA® is indicated for the treatment of adults with active psoriatic arthritis.

TREMFYA® is indicated for the treatment of adults with moderately to severely active ulcerative colitis.

SELECTED IMPORTANT SAFETY INFORMATION

TREMFYA® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients. Serious hypersensitivity reactions, including anaphylaxis, have been reported. TREMFYA® may increase the risk of infection. Do not initiate treatment in patients with clinically important active infection until the infection resolves or is adequately treated. If such an infection develops, discontinue TREMFYA® until infection resolves. Evaluate for tuberculosis before treating with TREMFYA®. Avoid use of live vaccines in patients treated with TREMFYA®. Please see related and other Important Safety Information on the reverse.

cp-82628v5

Tremfya® (guselkumab)

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

TREMFYA® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA®. Some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA® and initiate appropriate therapy.

Infections

TREMFYA® may increase the risk of infection. Treatment with TREMFYA® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)

Evaluate patients for TB infection prior to initiating treatment with TREMFYA®. Initiate treatment of latent TB prior to administering TREMFYA®. Monitor patients for signs and symptoms of active TB during and after TREMFYA® treatment. Do not administer TREMFYA® to patients with active TB infection.

Immunizations

Prior to initiating TREMFYA®, complete all age-appropriate vaccinations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA®.

ADVERSE REACTIONS

Most common adverse reactions associated with TREMFYA® include: plaque psoriasis and psoriatic arthritis adverse reactions (≥1%): upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections. Ulcerative colitis adverse reactions: induction (≥2%): respiratory tract infections; maintenance (≥3%): injection site reactions, arthralgia, and upper respiratory tract infections.

The overall safety profile observed in patients with psoriatic arthritis is generally consistent with the safety profile in patients with plaque psoriasis, with the addition of bronchitis and neutrophil count decreased.

Please read the full Prescribing Information and Medication Guide for TREMFYA®. Provide the Medication Guide to your patients and encourage discussion.

Dosage Forms and Strengths: TREMFYA® is available in a 100 mg/mL prefilled syringe and One-Press patient-controlled injector for subcutaneous injection, a 200 mg/2 mL prefilled syringe and prefilled pen (TREMFYA® PEN) for subcutaneous injection, and a 200 mg/20 mL (10 mg/mL) single-dose vial for intravenous infusion.

cp-82625v6

DISCLOSURES

In adherence with PhRMA guidelines, spouses or other guests are not permitted to attend company-sponsored programs.

For all attendees, please be advised that information such as your name and the value and purpose of any educational item, meal, or other items of value you receive may be publicly disclosed. If you are licensed in any state or other jurisdiction, or are an employee or contractor of any organization or governmental entity, that limits or prohibits meals from pharmaceutical companies, please identify yourself so that you (and we) are able to comply with such requirements.

Please note that the company prohibits the offering of gifts, gratuities, or meals to federal government employees/officials. Thank you for your cooperation.

The consultants are paid speakers for Janssen Biotech, Inc., a Johnson & Johnson company. The speakers are presenting on behalf of Janssen and must present information in compliance with FDA requirements applicable to Janssen.

FDA=Food and Drug Administration.

Tremfya® (guselkumab)

Johnson&Johnson

Janssen Biotech, Inc., a Johnson & Johnson company, 800 Ridgeview Drive, Horsham, PA 19044